BidaskClub upgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a hold rating to a buy rating in a research note published on Tuesday.

MCRB has been the subject of several other research reports. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the company a buy rating in a research note on Thursday, May 4th. Cantor Fitzgerald set a $16.00 price target on shares of Seres Therapeutics and gave the company a buy rating in a research note on Thursday, May 4th. Zacks Investment Research cut shares of Seres Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 12th. Finally, Cowen and Company reissued a buy rating on shares of Seres Therapeutics in a research note on Friday, May 19th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Seres Therapeutics currently has an average rating of Buy and a consensus price target of $21.33.

Shares of Seres Therapeutics (MCRB) traded down 0.58% during mid-day trading on Tuesday, reaching $13.65. 176,177 shares of the company’s stock traded hands. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09. The company’s 50-day moving average price is $11.75 and its 200-day moving average price is $10.47. The stock’s market capitalization is $551.32 million.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.02. Seres Therapeutics had a negative net margin of 441.10% and a negative return on equity of 68.86%. The business had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $3 million. During the same quarter in the prior year, the company posted ($0.50) EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Analysts anticipate that Seres Therapeutics will post ($2.65) earnings per share for the current year.

WARNING: “Seres Therapeutics, Inc. (NASDAQ:MCRB) Raised to Buy at BidaskClub” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/seres-therapeutics-inc-nasdaqmcrb-raised-to-buy-at-bidaskclub/1461834.html.

Several institutional investors have recently modified their holdings of the company. American International Group Inc. raised its position in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Seres Therapeutics during the first quarter valued at approximately $136,000. Bank of Montreal Can raised its position in shares of Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,829 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 279 shares in the last quarter. Hedge funds and other institutional investors own 75.53% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.